Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Oncolytics Biotech Inc ONCY


Primary Symbol: T.ONC

Healthcare Biotechnology
Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and... see more

TSX:ONC - Post Discussion

Oncolytics Biotech Inc > SITC 2024 - Nov.06 - Nov.10 - Houston TX.
View:
Post by Noteable on Nov 04, 2024 11:52am

SITC 2024 - Nov.06 - Nov.10 - Houston TX.

Keynote Address: " What is T Cell Exhaustion?"

https://www.sitcancer.org/2024/schedule/sitc24-annualmeeting
Comment by Noteable on Nov 04, 2024 12:01pm
Session 107c: Timing and Combination of Systemic Therapies in Solid Cancers Framework for Novel Combination Immunotherapy Development Informed by the TME - Jason Luke, MD, FACP - UPMC Hillman Cancer Center Session 107d: NK Cells and Innate Immunity Harnessing Innate Immune Receptors in Cancer Immunotherapy - Marco Colonna, MD - Washington University School of Medicine, St ...more  
Comment by Noteable on Nov 04, 2024 12:19pm
Wednesday, Nov. 6, 2024  - Tumor Infiltrating Lymphocytes (TIL) Symposium Wednesday, Nov. 6, 2024 - Beyond Checkpoint Inhibitors: New Immuno-oncology Modalities and Approaches Thursday, Nov. 7, 2024  - Primer on Tumor Immunology and Cancer Immunotherapy - Modulating the Tumor Microenvironment with T cell Bispecifics   Sumit K. Subudhi, MD, PhD – The ...more  
Comment by Noteable on Nov 09, 2024 10:36am
https://stockhouse.com/companies/bullboard?symbol=t.onc&postid=36304610
Oncolytics Biotech Inc
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Dealroom for high-potential pre-IPO opportunities